A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine; T-DM1)
Latest Information Update: 27 Oct 2023
At a glance
- Drugs Tucatinib (Primary) ; Trastuzumab emtansine
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors Cascadian Therapeutics; Seagen
- 12 Sep 2023 Results (n=283 from studies ONT-380-004,ONT-380-005 and SGNTUC-017) assessing Population Pharmacokinetic Analysis of Tucatinib in Healthy Subjects & Subjects With HER2+ Metastatic Breast Cancer or Metastatic Colorectal Cancer presented at the 2023 American College of Clinical Pharmacology Annual Meeting
- 19 Apr 2020 Status changed from active, no longer recruiting to completed.
- 07 Feb 2020 Planned End Date changed from 1 Jan 2020 to 31 Mar 2020.